Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
Apollomics完成了中國Uproleselan（Apl-106）3期橋接研究的患者入組——預計將在2025年上半年公佈頭條數據
Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
Apollomics完成了中國Uproleselan（Apl-106）3期橋接研究的患者入組——預計將在2025年上半年公佈頭條數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。